Literature DB >> 30970194

Lowering of Amyloid-Beta by β-Secretase Inhibitors - Some Informative Failures.

David S Knopman1.   

Abstract

Mesh：

Substances：

Year:  2019        PMID： 30970194     DOI： 10.1056/NEJMe1903193

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  29 in total

Review 1.  The case for low-level BACE1 inhibition for the prevention of Alzheimer disease.

Authors:  Eric McDade; Iryna Voytyuk; Paul Aisen; Randall J Bateman; Maria C Carrillo; Bart De Strooper; Christian Haass; Eric M Reiman; Reisa Sperling; Pierre N Tariot; Riqiang Yan; Colin L Masters; Robert Vassar; Stefan F Lichtenthaler
Journal:  Nat Rev Neurol       Date:  2021-09-21       Impact factor: 42.937

Review 2.  Lipid metabolism and Alzheimer's disease: clinical evidence, mechanistic link and therapeutic promise.

Authors:  Fei Yin
Journal:  FEBS J       Date:  2022-01-07       Impact factor: 5.622

Review 3.  Is the p3 Peptide (Aβ17-40, Aβ17-42) Relevant to the Pathology of Alzheimer's Disease?1.

Authors:  Ariel J Kuhn; Jevgenij Raskatov
Journal:  J Alzheimers Dis       Date:  2020       Impact factor: 4.472

4.  Alzheimer's Disease "Non-amyloidogenic" p3 Peptide Revisited: A Case for Amyloid-α.

Authors:  Ariel J Kuhn; Benjamin S Abrams; Stella Knowlton; Jevgenij A Raskatov
Journal:  ACS Chem Neurosci       Date:  2020-05-22       Impact factor: 4.418

Review 5.  The search for Alzheimer disease therapeutics - same targets, better trials?

Authors:  Michael S Rafii; Paul S Aisen
Journal:  Nat Rev Neurol       Date:  2020-11       Impact factor: 42.937

6.  EVOO Polyphenols Relieve Synergistically Autophagy Dysregulation in a Cellular Model of Alzheimer's Disease.

Authors:  Manuela Leri; Andrea Bertolini; Massimo Stefani; Monica Bucciantini
Journal:  Int J Mol Sci       Date:  2021-07-05       Impact factor: 5.923

Review 7.  Perspectives for New and More Efficient Multifunctional Ligands for Alzheimer's Disease Therapy.

Authors:  Agnieszka Zagórska; Anna Jaromin
Journal:  Molecules       Date:  2020-07-23       Impact factor: 4.411

8.  Safety, Tolerability, Pharmacokinetics, and Pharmacodynamic Effects of PF-06751979, a Potent and Selective Oral BACE1 Inhibitor: Results from Phase I Studies in Healthy Adults and Healthy Older Subjects.

Authors:  Ruolun Qiu; Jae Eun Ahn; Robert Alexander; Michael A Brodney; Ping He; Claire Leurent; Jessica Mancuso; Richard A Margolin; Ekaterina Tankisheva; Danny Chen
Journal:  J Alzheimers Dis       Date:  2019       Impact factor: 4.472

9.  Commentary: Using human genetics to guide the repurposing of medicines.

Authors:  Jonas Bovijn; Jenny C Censin; Cecilia M Lindgren; Michael V Holmes
Journal:  Int J Epidemiol       Date:  2020-08-01       Impact factor: 7.196

10.  Further analyses of the safety of verubecestat in the phase 3 EPOCH trial of mild-to-moderate Alzheimer's disease.

Authors:  Michael F Egan; Yuki Mukai; Tiffini Voss; James Kost; Julie Stone; Christine Furtek; Erin Mahoney; Jeffrey L Cummings; Pierre N Tariot; Paul S Aisen; Bruno Vellas; Christopher Lines; David Michelson
Journal:  Alzheimers Res Ther       Date:  2019-08-07       Impact factor: 6.982
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.